<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INDINAVIR SULFATE</span><br/>(in-din'a-vir)<br/><span class="topboxtradename">Crixivan<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Prototype: </b>Saquinavir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg, 333 mg, 400 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Indinavir is an HIV protease inhibitor. HIV protease is an enzyme required to produce the polyprotein precursors of the functional
         proteins in infectious HIV.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Protease inhibitors prevent cleavage of the HIV viral polyproteins, resulting in formation of immature noninfectious virus
         particles. Indinavir binds to the protease active site and thus inhibits activity of the enzyme.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV infection, usually in combination with other antiretroviral agents or protease inhibitors.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to indinavir; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic dysfunction, renal impairment, history of nephrolithiasis, history of adverse responses to other protease inhibitors.
         Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 800 mg (2 <small>x</small> 400 mg) q8h 1 h before or 2 h after meal<br/><span class="rdage">With ritonavir:</span> <span class="rdroute"></span> 800 mg b.i.d. plus 100Â–200 mg ritonavir b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with water on an empty stomach 1 h before or 2 h after meal; if needed, may be given with a very light meal or beverage.</li>
<li>
            				Note: When didanosine and indinavir are ordered concurrently, give each on empty stomach at least 1 h apart.
            			
         </li>
<li>Do not administer concurrently with midazolam or triazolam.</li>
<li>Store tightly closed with desiccant in original bottle.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Fatigue, headache, insomnia, dizziness, somnolence, nervousness, agitation, anxiety, paresthesia, peripheral neuropathy, tremor,
      vertigo. <span class="typehead">CV:</span> Palpitations. <span class="typehead">Hematologic:</span> Anemia, splenomegaly, lymphadenopathy. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> diarrhea, abdominal discomfort, dyspepsia, stomatitis, anorexia, dry mouth, cholecystitis, cholestasis, constipation, flatulence. <span class="typehead">Skin:</span> Body odor, rash, pruritus, seborrhea, skin ulceration, dry skin, sweating, urticaria. <span class="typehead">Other:</span> Myalgia, allergic reaction, bronchitis, cough, rhinitis, taste alterations, visual disturbances, hyperglycemia, diabetes,
      kidney stones. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Rifabutin,</b>
<b>rifampin</b> significantly decrease indinavir levels. <b>Ketoconazole</b> significantly increases indinavir levels. Indinavir could inhibit the metabolism and increase the toxicity of <b>midazolam,</b>
<b> sildenafil,</b>
<b> tadalafil,</b>
<b>trazodone,</b>
<b>triazolam,</b>
<b>vardenafil.</b> Indinavir and <b>didanosine</b> should be administered at least 1 h apart on empty stomach to permit full absorption of each; increased <b>ergotamine</b> toxicity with indinavir. <span class="typehead">Herbal:</span>
<b>St. John's wort, garlic</b> decreases <span class="classification">antiretroviral</span> activity of indinavir. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; a meal high in calories, fat, and protein significantly reduces absorption. <span class="typehead">Distribution:</span> 60% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P4503A4 (CYP3A4). <span class="typehead">Elimination:</span> Excreted primarily in feces (&gt;80%), 20% excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC with differential and platelet count, liver function tests, CPK, urinalysis, and serum amylase periodically.</li>
<li>Assess for S&amp;S of renal dysfunction, respiratory dysfunction, GI distress, and other common adverse effects.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn drug interactions and potential adverse reactions. Drink plenty of liquid to minimize risk of renal stones.</li>
<li>Notify physician of flank pain, hematuria, S&amp;S of jaundice, or other distressing adverse effects.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>